)
Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Among the 18% of adults who report having ever used GLP-1 drugs, the vast majority (84%) say they have been diagnosed with at least one of the predominant conditions these drugs are prescribed to treat, including obesity or being overweight in the past five years (77%), or ever being diagnosed with diabetes (49%) or heart disease (21%)
Most people who report bad experiences moved up too quickly
10.1111/j.1440-1819.1996.tb00573.x 54
The placebo group (discontinuation group) regained 6.9% of body weight over 48 weeks, while the continuation group lost an additional 7.9%
Whether that closes the gap to retatrutide depends on the actual data, but the strategic logic adding a second mechanism to semaglutide because semaglutide alone can no longer compete on efficacy is now obvious
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
